Combining phase and magnitude information for contrast agent quantification in dynamic contrast-enhanced MRI using statistical modeling

Improved repeatability of dynamic contrast-enhanced MRI using the complex MRI signal to derive arterial input functions: a test-retest study in prostate cancer patients

Purpose

The arterial input function (AIF) is a major source of uncertainty in tracer kinetic (TK) analysis of dynamic contrast‐enhanced (DCE)‐MRI data. The aim of this study was to investigate the repeatability of AIFs extracted from the complex signal and of the resulting TK parameters in prostate cancer patients.

Methods

Twenty‐two patients with biopsy‐proven prostate cancer underwent a 3T MRI exam twice. DCE‐MRI data were acquired with a 3D spoiled gradient echo sequence. AIFs were extracted from the magnitude of the signal (AIF_MAGN), phase (AIF_PHASE), and complex signal (AIF_COMPLEX). The Tofts model was applied to extract K^trans, k_ep and v_e. Repeatability of AIF curve characteristics and TK parameters was assessed with the within‐subject coefficient of variation (wCV).

Results

The wCV for peak height and full width at half maximum for AIF_COMPLEX (7% and 8%) indicated an improved repeatability compared to AIF_MAGN (12% and 12%) and AIF_PHASE (12% and 7%). This translated in lower wCV values for K^trans (11%) with AIF_COMPLEX in comparison to AIF_MAGN (24%) and AIF_PHASE (15%). For k_ep, the wCV was 16% with AIF_MAGN, 13% with AIF_PHASE, and 13% with AIF_COMPLEX.

Conclusion

Repeatability of AIF_PHASE and AIF_COMPLEX is higher than for AIF_MAGN, resulting in a better repeatability of TK parameters. Thus, use of either AIF_PHASE or AIF_COMPLEX improves the robustness of quantitative analysis of DCE‐MRI in prostate cancer.

Peptide-functionalized NaGdF4 nanoparticles for tumor-targeted magnetic resonance imaging and effective therapy

Metallic nanoparticles showed potent efficacy for diagnosis and therapy of cancer, but their clinical applications are limited by their poor tumor-targeting ability. Herein, peptide-functionalized 9 nm NaGdF₄ nanoparticles (termed as, NaGdF₄@bp-peptide NPs) have been synthesized through the Gd–phosphate coordination reaction of the spherical NaGdF₄ nanoparticles with phosphopeptides (sequence: KLAKLAKKLAKLAKG(p-S)GAKRGARSTA, p-S means phosphorylated serine) including a p32 protein binding motif incorporating a cell-penetrating function, and a proapoptotic domain. The NaGdF₄@bp-peptide NPs are ready to be efficiently internalized by cancer cells; they show a much higher cytotoxicity in MCF-7 breast cancer cells than the casein phosphopeptide (CPP) modified NaGdF₄ nanoparticles (termed as, NaGdF₄@CPP NPs). Using mouse-bearing MCF-7 breast cancer as a model system, the in vivo experimental results demonstrate that NaGdF₄@bp-peptide NPs have integration of T₁-weighted magnetic resonance imaging (MRI) contrast and tumor-targeting functionalities, and are able to suppress tumor growth without causing systemic toxicity.

NaGdF₄@bp-peptide nanoparticles have been used as a T₁-weighted MR contrast agent with active-tumor targeting and antitumor ability.

Renal Clearable Peptide Functionalized NaGdF4 Nanodots for High-Efficiency Tracking Orthotopic Colorectal Tumor in Mouse

The effective delivery of bioimaging probes to a selected cancerous tissue has extensive significance for biological studies and clinical investigations. Herein, the peptide functionalized NaGdF₄ nanodots (termed as, pPeptide-NaGdF₄ nanodots) have been prepared for highly efficient magnetic resonance imaging (MRI) of tumor by formation of Gd-phosphonate coordinate bonds among hydrophobic NaGdF₄ nanodots (4.2 nm in diameter) with mixed phosphorylated peptide ligands including a tumor targeting phosphopeptide and a cell penetrating phosphopeptide. The tumor targeting pPeptide-NaGdF₄ nanodots have paramagnetic property with ultrasmall hydrodynamic diameter (HD, c.a., 7.3 nm) which greatly improves their MRI contrast ability of tumor and facilitates renal clearance. In detail, the capability of the pPeptide-NaGdF₄ nanodots as high efficient contrast agent for in vivo MRI is evaluated successfully through tracking small drug induced orthotopic colorectal tumor (c.a., 195 mm³ in volume) in mouse.

DCE-MRI of the prostate using shutter-speed vs. Tofts model for tumor characterization and assessment of aggressiveness

PURPOSE

To quantify Tofts model (TM) and shutter-speed model (SSM) perfusion parameters in prostate cancer (PCa) and noncancerous peripheral zone (PZ) and to compare the diagnostic performance of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to Prostate Imaging and Reporting and Data System (PI-RADS) classification for the assessment of PCa aggressiveness.

MATERIALS AND METHODS

Fifty PCa patients (mean age 60 years old) who underwent MRI at 3.0T followed by prostatectomy were included in this Institutional Review Board-approved retrospective study. DCE-MRI parameters (K^trans , v_e , k_ep [TM&SSM] and intracellular water molecule lifetime τ_i [SSM]) were determined in PCa and PZ. Differences in DCE-MRI parameters between PCa and PZ, and between models were assessed using Wilcoxon signed-rank tests. Receiver operating characteristic (ROC) analysis for differentiation between PCa and PZ was performed for individual and combined DCE-MRI parameters. Diagnostic performance of DCE-MRI parameters for identification of aggressive PCa (Gleason ≥8, grade group [GG] ≥3 or pathology stage pT3) was assessed using ROC analysis and compared with PI-RADSv2 scores.

RESULTS

DCE-MRI parameters were significantly different between TM and SSM and between PZ and PCa (P < 0.037). Diagnostic performances of TM and SSM for differentiation of PCa from PZ were similar (highest AUC TM: K^trans +k_ep 0.76, SSM: τ_i +k_ep 0.80). PI-RADS outperformed TM and SSM DCE-MRI for identification of Gleason ≥8 lesions (AUC PI-RADS: 0.91, highest AUC DCE-MRI: K^trans +τ_i SSM 0.61, P = 0.002). The diagnostic performance of PI-RADS and DCE-MRI for identification of GG ≥3 and pT3 PCa was not significantly different (P > 0.213).

CONCLUSION

SSM DCE-MRI did not increase the diagnostic performance of DCE-MRI for PCa characterization. PI-RADS outperformed both TM and SSM DCE-MRI for identification of aggressive cancer.

LEVEL OF EVIDENCE

3 Technical Efficacy: Stage 2 J. MAGN. RESON. IMAGING 2017;46:837-849.